Comparison of baseline patient characteristics among POD groups
| Variable . | Total* n = 455 n (%) . | PRF/POD6 n = 65 n (%) . | POD6-24 n = 153 n (%) . | POD>24 n = 237 n (%) . | P . |
|---|---|---|---|---|---|
| Age at diagnosis | |||||
| Median (range) | 62 (32-93) | 66 (32-86) | 63 (38-87) | 60 (32-93) | .002 |
| Mean | 61 | 63 | 63 | 59 | |
| Sex | |||||
| Female | 104 (23) | 12 (18) | 35 (23) | 57 (24) | .636 |
| Male | 351 (77) | 53 (82) | 118 (77) | 180 (76) | |
| ECOG PS | |||||
| 0-1 | 346 (94) | 52 (93) | 112 (90) | 182 (96) | .154 |
| ≥2 | 24 (6) | 4 (7) | 12 (10) | 8 (4) | |
| Ann Arbor stage | |||||
| 1-3 | 62 (14) | 7 (11) | 12 (8) | 43 (19) | .011 |
| 4 | 378 (86) | 57 (89) | 135 (92) | 186 (81) | |
| Splenomegaly | |||||
| Yes | 210 (57) | 32 (55) | 86 (67) | 92 (51) | .016 |
| No | 157 (43) | 26 (45) | 42 (33) | 89 (49) | |
| LN >5 cm | |||||
| Yes | 72 (23) | 12 (24) | 29 (27) | 31 (19) | .386 |
| No | 247 (77) | 39 (76) | 80 (73) | 128 (81) | |
| B symptoms | |||||
| Yes | 126 (31) | 15 (25) | 61 (45) | 50 (24) | <.001 |
| No | 276 (69) | 45 (75) | 75 (55) | 156 (76) | |
| MIPI risk score | |||||
| Low risk | 74 (35) | 10 (27) | 17 (22) | 47 (47) | .002 |
| Intermediate risk | 72 (34) | 10 (27) | 29 (38) | 33 (33) | |
| High risk | 67 (31) | 17 (46) | 30 (39) | 20 (20) | |
| Ki67 | |||||
| ≤30% | 93 (50) | 13 (36) | 32 (40) | 48 (68) | <.001 |
| >30% | 94 (50) | 23 (64) | 48 (60) | 23 (32) | |
| Complex karyotype | |||||
| Yes | 30 (20) | 3 (14) | 20 (35) | 7 (10) | .001 |
| No | 121 (80) | 18 (86) | 37 (65) | 66 (90) | |
| Histology | |||||
| Blastoid | 61 (20) | 15 (33) | 28 (26) | 18 (12) | .001 |
| Nonblastoid | 245 (80) | 31 (67) | 79 (74) | 135 (88) | |
| Diagnosis to treatment interval, d | |||||
| 0-90 | 345 (83) | 54 (92) | 128 (90) | 163 (76) | <.001 |
| >90 | 71 (17) | 5 (8) | 14 (10) | 52 (24) | |
| Not recorded | 39 | 6 | 11 | 22 |
| Variable . | Total* n = 455 n (%) . | PRF/POD6 n = 65 n (%) . | POD6-24 n = 153 n (%) . | POD>24 n = 237 n (%) . | P . |
|---|---|---|---|---|---|
| Age at diagnosis | |||||
| Median (range) | 62 (32-93) | 66 (32-86) | 63 (38-87) | 60 (32-93) | .002 |
| Mean | 61 | 63 | 63 | 59 | |
| Sex | |||||
| Female | 104 (23) | 12 (18) | 35 (23) | 57 (24) | .636 |
| Male | 351 (77) | 53 (82) | 118 (77) | 180 (76) | |
| ECOG PS | |||||
| 0-1 | 346 (94) | 52 (93) | 112 (90) | 182 (96) | .154 |
| ≥2 | 24 (6) | 4 (7) | 12 (10) | 8 (4) | |
| Ann Arbor stage | |||||
| 1-3 | 62 (14) | 7 (11) | 12 (8) | 43 (19) | .011 |
| 4 | 378 (86) | 57 (89) | 135 (92) | 186 (81) | |
| Splenomegaly | |||||
| Yes | 210 (57) | 32 (55) | 86 (67) | 92 (51) | .016 |
| No | 157 (43) | 26 (45) | 42 (33) | 89 (49) | |
| LN >5 cm | |||||
| Yes | 72 (23) | 12 (24) | 29 (27) | 31 (19) | .386 |
| No | 247 (77) | 39 (76) | 80 (73) | 128 (81) | |
| B symptoms | |||||
| Yes | 126 (31) | 15 (25) | 61 (45) | 50 (24) | <.001 |
| No | 276 (69) | 45 (75) | 75 (55) | 156 (76) | |
| MIPI risk score | |||||
| Low risk | 74 (35) | 10 (27) | 17 (22) | 47 (47) | .002 |
| Intermediate risk | 72 (34) | 10 (27) | 29 (38) | 33 (33) | |
| High risk | 67 (31) | 17 (46) | 30 (39) | 20 (20) | |
| Ki67 | |||||
| ≤30% | 93 (50) | 13 (36) | 32 (40) | 48 (68) | <.001 |
| >30% | 94 (50) | 23 (64) | 48 (60) | 23 (32) | |
| Complex karyotype | |||||
| Yes | 30 (20) | 3 (14) | 20 (35) | 7 (10) | .001 |
| No | 121 (80) | 18 (86) | 37 (65) | 66 (90) | |
| Histology | |||||
| Blastoid | 61 (20) | 15 (33) | 28 (26) | 18 (12) | .001 |
| Nonblastoid | 245 (80) | 31 (67) | 79 (74) | 135 (88) | |
| Diagnosis to treatment interval, d | |||||
| 0-90 | 345 (83) | 54 (92) | 128 (90) | 163 (76) | <.001 |
| >90 | 71 (17) | 5 (8) | 14 (10) | 52 (24) | |
| Not recorded | 39 | 6 | 11 | 22 |
LN, lymph node.
Total number <455 in some categories because of missing data.